单抗药物

Search documents
趋势研判!2025年中国单抗药物行业产业链、发展背景、市场规模、竞争格局及发展趋势分析:国产化替代进程加速[图]
Chan Ye Xin Xi Wang· 2025-08-27 01:21
Overview - The monoclonal antibody (mAb) market in China is still in its early stages, with many overseas mAbs not yet approved domestically. The high cost of these drugs limits accessibility for many patients with lower payment capabilities. However, the market penetration of mAbs is gradually increasing due to their significant advantages over traditional drugs, updates to the national medical insurance catalog, and rising national income levels. The market size of China's mAb industry is projected to reach 131.5 billion yuan in 2024, representing a year-on-year growth of 30.85% [1][5]. Industry Chain - The upstream of the mAb industry includes suppliers of raw materials such as cell culture media, enzymes, antibodies, reagents, consumables, and packaging materials, as well as core equipment suppliers like bioreactors and purification devices. The midstream consists of mAb research and production companies, while the downstream includes hospitals, DTP pharmacies, retail pharmacies, and online channels. Hospitals are the most critical distribution channel for mAbs in China, especially for drugs listed in the medical insurance catalog [3][5]. Development Background - The application of mAbs in cancer treatment is widespread, with the number of new cancer cases in China projected to reach 5.064 million in 2024, a year-on-year increase of 2.61%. This growing cancer population drives the demand for mAbs. Additionally, mAbs have shown efficacy in treating other diseases, such as asthma and inflammatory bowel diseases, providing new development opportunities for the mAb industry [4][5]. Current Status - Since the launch of the first therapeutic mAb in 1986, the mAb market has rapidly developed, with significant products like trastuzumab and adalimumab emerging. By 2024, the global mAb market size is expected to reach 273.3 billion USD, with a year-on-year growth of 9.15% [4][5]. Competitive Landscape - In the global pharmaceutical market, mAbs are becoming a cornerstone of biopharmaceuticals, with 8 mAbs appearing in the top 20 global drug sales rankings in 2024. The success of mAbs in treating tumors and immune diseases is notable, and advancements in biopharmaceutical technology may expand their role in treating infectious diseases [5][6]. Domestic Market Dynamics - In 2024, only 7 mAbs are among the top 30 chemical and biological drugs sold in Chinese hospitals, indicating significant room for growth in the domestic mAb market. The market is expected to expand further as domestic companies gain market share [7][8]. Company Analysis - Domestic companies like BeiGene, Innovent Biologics, Junshi Biosciences, and others are increasingly capturing market share previously dominated by multinational corporations. For instance, BeiGene's Tislelizumab leads in the PD-1 mAb market in China, while Innovent's Sintilimab and Junshi's Toripalimab also hold significant positions [8][9]. Future Trends - The quality and efficacy of domestic mAbs are expected to improve with ongoing advancements in research and production technologies. This may lead to a further increase in market share, breaking the monopoly of multinational companies. Additionally, the application of mAbs is anticipated to expand beyond cancer and autoimmune diseases to include infectious and transmissible diseases [11].
东吴证券给予新诺威买入评级,持续加码研发,全面布局ADC、mRNA和单抗药物
Mei Ri Jing Ji Xin Wen· 2025-08-17 14:39
Group 1 - The core viewpoint of the report is that Dongwu Securities has given a "buy" rating for XinNuoWei (300765.SZ) based on its performance and potential in the biopharmaceutical sector [2] - The company experienced a slight revenue growth in H1, but a significant decline in profits [2] - The EGFR ADC data presented at the AACR conference is seen as a potential "blockbuster" drug, indicating strong future prospects [2] - The company is actively increasing its investment in research and development, focusing on ADC, mRNA, and monoclonal antibody drugs [2]
新诺威(300765):持续加码研发,EGFRADC下半年有望启动首个海外注册临床
Soochow Securities· 2025-08-17 14:22
Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company is continuously increasing its R&D investments, with a comprehensive focus on ADC, mRNA, and monoclonal antibody drugs. In the first half of the year, three new ADCs entered clinical stages domestically, and three ADCs received FDA clinical approval. The clinical progress of multiple ADCs is rapid, with SYS6010 completing the first patient enrollment in a Phase 3 clinical trial for 2L+ EGFRmt NSCLC in April, with expectations for market launch as early as 2027. The overseas clinical trials are accelerating, with over 100 patients enrolled, and the first overseas registration clinical trial is expected to start in the second half of the year, representing a potential blockbuster product [3][9] - The company achieved total revenue of 1.05 billion yuan in the first half of 2025, a year-on-year increase of 7.99%. The revenue from functional foods and raw materials was 933 million yuan, a slight decrease of 0.69%, while biopharmaceutical revenue contributed 94 million yuan. R&D expenses increased by 80.81% to 455 million yuan, and selling expenses rose by 70.96% to 125 million yuan. The net profit attributable to the parent company was -3 million yuan, a decline of 102% [8][9] - The EGFR ADC has shown promising data at the AACR conference, with a total of 232 patients enrolled by the end of 2024, including 137 NSCLC patients. The overall safety profile is favorable, with a 90% objective response rate (ORR) in 2L EGFRmt NSCLC patients and a 41.5% ORR in 3L+ EGFRmt NSCLC patients [8][9] Financial Projections - The company forecasts revenues of 2.39 billion yuan for 2025, 2.77 billion yuan for 2026, and 3.29 billion yuan for 2027, maintaining the "Buy" rating [1][9] - The report provides detailed financial metrics, including a projected net profit of 57.3 million yuan for 2025, with an EPS of 0.04 yuan per share [1][10]
石药集团(01093)上涨2.07%,报9.86元/股
Jin Rong Jie· 2025-08-05 03:58
Group 1 - The core viewpoint of the article highlights the performance and strategic focus of CSPC Pharmaceutical Group Limited, emphasizing its strong product portfolio in various therapeutic areas and its innovative drug development strategy [1][2][3] Group 2 - As of the first quarter of 2025, CSPC Pharmaceutical Group reported total revenue of 7.015 billion yuan and a net profit of 1.478 billion yuan [2] - The company’s stock price increased by 2.07% to 9.86 yuan per share, with a trading volume of 0.852 billion yuan as of 11:40 AM on August 5 [1]